Physician
Psychiatry
Dr. Mark E. Bangs, MD
Mark Bangs is an expert in the field of Psychiatry. He attended Indiana University School of Medicine. Indiana University School of Medicine is ranked 45 in research and 47 in primary care medicine Mark E. Bangs is a published physician. He published 20 publications, including: 'Fluoxetine-induced memory impairment in an adolescent.'
Publications
- Long-Term, Open-Label, Safety Study of Edivoxetine 12 to 18 mg Once Daily as Adjunctive Treatment for Patients With Major Depressive Disorder Who Are Partial Responder...
- Meta-Analysis of Suicide-Related Behavior or Ideation in Child, Adolescent, and Adult Patients Treated with Atomoxetine.
- A Double-Blind Efficacy and Safety Study of Duloxetine Flexible Dosing in Children and Adolescents with Major Depressive Disorder.
- A Double-Blind Efficacy and Safety Study of Duloxetine Fixed Doses in Children and Adolescents with Major Depressive Disorder.
- A cohort study of the risk of seizures in a pediatric population treated with atomoxetine or stimulant medications.
- Atomoxetine and cerebrovascular outcomes in adults.
- Meta-analysis of suicide-related behavior events in patients treated with atomoxetine.
- Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and...
- Meta-analysis of aggression or hostility events in randomized, controlled clinical trials of atomoxetine for ADHD.
- The risk of bleeding with duloxetine treatment in patients who use nonsteroidal anti-inflammatory drugs (NSAIDs): analysis of placebo-controlled trials and post-market...
- Urinary incontinence with donepezil treatment in hospitalized children and adolescents with attention deficit hyperactivity disorder.
- Safety and tolerability of atomoxetine over 3 to 4 years in children and adolescents with ADHD.
- Fluoxetine-induced memory impairment in an adolescent.
- Atomoxetine pharmacokinetics in healthy Chinese subjects and effect of the CYP2D6*10 allele.
- Seizure risk in patients with attention-deficit-hyperactivity disorder treated with atomoxetine.
- Efficacy and safety of atomoxetine in adolescents with attention-deficit/hyperactivity disorder and major depression.
- Hepatic events associated with atomoxetine treatment for attention-deficit hyperactivity disorder.
- Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder.
- Effect of atomoxetine on Tanner stage sexual development in children and adolescents with attention deficit/hyperactivity disorder: 18-month results from a double-blin...
Schools
Indiana University School of Medicine
Baylor
Ind University School Med
Doctors Specialties
- Psychiatry
Accepted Insurances
- Choice Plus POS II
- Blue Cross Blue Shield of Illinois PPO
- First Health (Coventry Health Care) PPO
- HealthLink PPO
- MultiPlan PPO
- PHCS Network PPO
Education
-
Indiana University School of Medicine -
Baylor College of Medicine
Helpful Reviews
Similar Doctors
|
Dr. Jennifer H. Carlos, MD |
|
Dr. Leigh A. Dooley, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Bruce J. Kinon, MD |
|
|
Dr. Tyler C. Flaningham, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Padmaja C. Rao, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sanjay Mishra, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James Shoot, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shiela L. Irick, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nadia K. Al-Guboori, MD |